Related Experiment Video
Updated: Mar 24, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Isavuconazonium sulfate for the treatment of fungal infection
R C Walker1, J D Zeuli2, Z Temesgen3
1Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Abstract:
Isavuconazole is a new azole antifungal drug with a broad antifungal spectrum that includes yeasts, molds and dimorphic fungi. Its prodrug, isavuconazonium sulfate, is currently approved in the United States and Europe for the treatment of the two of the most common and most challenging invasive fungal infections in clinical practice, invasive aspergillosis and invasive mucormycosis. It is available in both oral and intravenous formulations for once-a-day dosing and has favorable safety profile and drug interaction potential in comparison to voriconazole. Its role in the treatment of other fungal infections, besides aspergillosis and mucormycosis, remains to be determined. Similarly, its efficacy in prophylaxis against invasive fungal infections or its utility in patients with prior azole exposure is yet to be elucidated in clinical studies.
Insights
Isavuconazole is a new antifungal medication approved for invasive aspergillosis and mucormycosis. It offers broad-spectrum coverage and a favorable safety profile compared to older azoles.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Background:
- Invasive fungal infections (IFIs) pose significant clinical challenges.
- Azole antifungals are crucial for treating IFIs.
- Newer agents are needed to address resistance and improve safety profiles.
Purpose of the Study:
- To review the current status and potential applications of isavuconazole.
- To highlight its efficacy in treating invasive aspergillosis and invasive mucormycosis.
- To compare its safety and drug interaction profile with voriconazole.
Main Methods:
- Review of clinical trial data and post-marketing surveillance.
- Pharmacokinetic and pharmacodynamic analyses.
- Comparative studies with existing antifungal therapies.
Main Results:
- Isavuconazole demonstrates broad-spectrum activity against yeasts, molds, and dimorphic fungi.
- Isavuconazonium sulfate is approved for invasive aspergillosis and mucormycosis.
- Favorable safety and lower drug interaction potential compared to voriconazole.
Conclusions:
- Isavuconazole is a valuable therapeutic option for specific IFIs.
- Further research is needed to explore its role in other fungal infections and prophylaxis.
- Its utility in azole-experienced patients requires further clinical investigation.
More Related Videos
Related Concept Videos
Antifungal Agents
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Drugs for Treatment of Ulcerative Colitis in IBD
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

